Oncology Medical News about mutation-positive;mutation negative;Lynch Syndrome;cancer incidence

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Ten years after mutation testing for Lynch syndrome: cancer incidence and outcome in mutation-positive and mutation-negative family members
Journal of Clinical Oncology, 09/03/09

Jarvinen HJ et al. – Long-term compliance in surveillance for CRC and EC exceeded 95% in Lynch syndrome. After 10 years of surveillance, no significant increase in mortality had occurred compared with mutation-negative relatives.

Methods

Cancer incidence and survival were determined after an 11.5-year follow-up in 242 mutation-positive and 367 mutation-negative participants
Participants in 57 Lynch syndrome families with 14 different mutations were at 50% risk
The median age was 36 years in mutation carriers and 42 years in mutation-negative participants
None had had cancer of the Lynch syndrome type

Results

Compliance was 95.9% for the colonic surveillance and 97.1% for the gynecologic surveillance
CRC occurred in 30 mutation-positive participants, and 74 participants had adenomas removed
Three patients died of CRC
Endometrial cancer (EC) occurred in 19 of 103 women at risk, and 48 women had prophylactic hysterectomy
Six of 112 women at risk had ovarian cancer
Cancer mortality rate was not significantly increased

<< Previous
CA 19-9 as a biomarker in advanced pancreatic cancer patients...

Next >>
p53 expression in tumor stromal fibroblasts is associated with...

Detection of BRAF mutations in the tumour and serum of patients enrolled in the AZD6244 (ARRY-142886) advanced melanoma phase II study
British Journal of Cancer, 11/04/09 Relevance Score: 77%